Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.37 USD
-0.02 (-6.12%)
Updated Aug 13, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Redhill Biopharma Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 62 | 86 | 64 | 6 |
Cost Of Goods | 3 | 33 | 49 | 37 | 2 |
Gross Profit | 3 | 28 | 36 | 27 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | -10 | 71 | 117 | 91 | 47 |
Income After Depreciation & Amortization | 13 | -43 | -81 | -64 | -43 |
Non-Operating Income | 21 | 14 | 0 | 0 | 1 |
Interest Expense | 10 | 42 | 17 | 13 | 0 |
Pretax Income | 24 | -72 | -98 | -76 | -42 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 24 | -72 | -98 | -76 | -42 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 24 | -72 | -98 | -76 | -42 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 15 | -35 | -79 | -62 | -42 |
Depreciation & Amortization (Cash Flow) | 2 | 8 | 2 | 2 | 1 |
Income After Depreciation & Amortization | 13 | -43 | -81 | -64 | -43 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 6.48 | 1.55 | 1.16 | 0.91 | 0.74 |
Diluted EPS Before Non-Recurring Items | 3.69 | -46.30 | -84.00 | -84.00 | -56.00 |
Diluted Net EPS (GAAP) | 4.00 | -48.00 | -84.00 | -84.00 | -56.00 |
Fiscal Year end for Redhill Biopharma Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 1.80 |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | 101.24 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | 101.24 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 2.81 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | 36.00 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | 36.00 |